Takeda Renews Global Licenses To Two Drugs With NPS Pharma Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has renewed its license for global rights to its Gattex (teduglutide) short bowel-syndrome and Preotact osteoporosis drugs with NPS Pharmaceuticals.